Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Julia Hoellenriegel, Elena Hartmann, MD, PhD, Andreas Rosenwald, MD, Susan O'Brien, MD, Michael Keating, MD, William G. Wierda, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 1631.

https://doi.org/10.1182/blood.V122.21.1631.1631

Published: 2013

Journal Articles

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Koichi Takahashi, MD, Mariela Sivina, PhD, Yasuhiro Oki, MD, Luis E Fayad, MD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Lianchun Xiao, Xuelin Huang, PhD, Kai Fu, MD, PhD, Wing Chung Chan, MD, Julie M Vose, MD, MBA, Hagop M. Kantarjian, MD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2709.

https://doi.org/10.1182/blood.V120.21.2709.2709

Published: 2012

Journal Articles

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Rozovski Uri, MD, David Harris, Ping Li, PhD, Zhiming Liu, Srdana Grgurevic, Susan Lerner, MS, Matthew Martinez, William G. Wierda, MD, Ph.D., Michael Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 3910.

https://doi.org/10.1182/blood.V120.21.3910.3910

Published: 2012

Journal Articles

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Julia Hoellenriegel, Dirk Zboralski, PhD, Zeev Estrov, William G. Wierda, MD, PhD, Michael Keating, MD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3878.

https://doi.org/10.1182/blood.V118.21.3878.3878

Published: 2011

Journal Articles

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, Stefan Faderl, MD, Pierce Sherry, Mark Brandt, Gautam Borthakur, Michael Keating, MD, Emil Freireich, Jorge E Cortes

Blood (2011) 118 (21): 2606.

https://doi.org/10.1182/blood.V118.21.2606.2606

Published: 2011

Journal Articles

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Farhad Ravandi, MD, Jeffrey Jorgensen, MD, PhD, Susan O'Brien, MD, Deborah A Thomas, MD, Stefan Faderl, MD, Sergernne York, RN, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Sherry Pierce, RN, BS, Michael Keating, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2458.

https://doi.org/10.1182/blood.V116.21.2458.2458

Published: 2010

Journal Articles

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Sabine Ponader, PhD, Joseph Buggy, PhD, Susan O'Brien, BA, MD, William G. Wierda, MD, PhD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 45.

https://doi.org/10.1182/blood.V116.21.45.45

Published: 2010

Journal Articles

Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB In Chronic Lymphocytic Leukemia (CLL) Cells

Zhiming Liu, Inbal Hazan-Halevy, David Harris, Ping Li, Alessandra Ferrajoli, MD, Stefan Faderl, MD, Michael Keating, MD, Zeev Estrov, MD

Blood (2010) 116 (21): 376.

https://doi.org/10.1182/blood.V116.21.376.376

Published: 2010

Journal Articles

The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies

Barbara Savoldo, MD, PhD, Carlos A. Ramos, MD, Catherine M. Bollard, MBChB, MD, Enli Liu, MD, MS, Martha Mims, MD, Michael Keating, MD, Adrian P. Gee, PhD, Zhuyong Mei, MD, Cliona M Rooney, PhD, Helen E Heslop, MD, Malcolm K. Brenner, MB, PhD, FRCP, FRCPath, Gianpietro Dotti, MD

Blood (2010) 116 (21): 3949.

https://doi.org/10.1182/blood.V116.21.3949.3949

Published: 2010

Journal Articles

The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway.

Yumin Hu, MD, PhD, Gang Chen, Yu Jia, Hui Zhang, Peng Huang, PhD, Kapil N. Bhalla, MD, Michael Keating, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 1739.

https://doi.org/10.1182/blood.V114.22.1739.1739

Published: 2009

Journal Articles

Plasma Circulating Ki-67 Index as a Biomarker and Prognostic Indicator in Patients with Chronic Lymphocytic Leukemia.

Jean-Marie Bruey, Zeev Estrov, Hagop M. Kantarjian, MD, Wanlong Ma, Chen-Hsiung Yeh, William Weirda, Amber Donahue, Susan O'Brien, Michael Keating, MD, Maher Albitar, MD

Blood (2009) 114 (22): 1261.

https://doi.org/10.1182/blood.V114.22.1261.1261

Published: 2009

Journal Articles

Symptom Profiles in Patients with Chronic Lymphocytic Leukemia: Validation and Application of the M. D. Anderson Symptom Inventory.

Xin Shelley Wang, MD, MPH, Tito R. Mendoza, PhD, Jackie B Broadway, APN, Gary M. Mobley, MS, Michael Keating, MD, Charles S. Cleeland, PhD, Alessandra Ferrajoli, MD.

Blood (2009) 114 (22): 1393.

https://doi.org/10.1182/blood.V114.22.1393.1393

Published: 2009

Journal Articles

Clinical Relevance of Circulating Poly-Ubiquitin as a Prognostic Indicator in Chronic Lymphocytic Leukemia.

Wanlong Ma, Hagop M. Kantarjian, MD, Xiuqiang Wang, Susan O'Brien, Chen-Hsiung Yeh, XI Zhang, Zeev Estrov, MD, Anthony Sferruzza, PhD, William Weirda, Michael Keating, MD, Maher Albitar, MD

Blood (2009) 114 (22): 1240.

https://doi.org/10.1182/blood.V114.22.1240.1240

Published: 2009

Journal Articles

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Xavier C. Badoux, MBBS, Carlos Bueso Ramos, MD, PhD, David Harris, B.S., Ping Li, Ph.D., Zhiming Liu, B.S., Jan Burger, M.D., Susan O'Brien, MD, Alessandra Ferrajoli, MD., Michael Keating, MD, Zeev Estrov, MD

Blood (2009) 114 (22): 1242.

https://doi.org/10.1182/blood.V114.22.1242.1242

Published: 2009

Journal Articles

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Lynne V Abruzzo, MD, PhD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 1248.

https://doi.org/10.1182/blood.V114.22.1248.1248

Published: 2009

Journal Articles

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Alessandra Ferrajoli, MD, Xavier C. Badoux, MBBS, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Manolo Pasia, RN, Bang-Ning Lee, PhD, James M. Reuben, PhD, Hagop Kantarjian, MD, Michael Keating, MD

Blood (2009) 114 (22): 206.

https://doi.org/10.1182/blood.V114.22.206.206

Published: 2009

Journal Articles

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 208.

https://doi.org/10.1182/blood.V114.22.208.208

Published: 2009

Journal Articles

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD, William G. Wierda, M.D., Ph.D,

Blood (2009) 114 (22): 3431.

https://doi.org/10.1182/blood.V114.22.3431.3431

Published: 2009

Journal Articles

Comparative Efficacy of First Line Therapies for Chronic Lymphocytic Leukemia: a Systematic Review and Meta-Analyses.

Ann Janssens, MD, Robin Foà, Michael Keating, MD, Mario Ouwens, PhD, Iain Tatt, PhD, Emma SC Carr, BSc, MSc, PhD

Blood (2009) 114 (22): 3432.

https://doi.org/10.1182/blood.V114.22.3432.3432

Published: 2009

Journal Articles

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Apostolia-Maria Tsimberidou, MD, PhD, William Wierda, MD, PhD, William Plunkett, Susan O'Brien, M.D., Thomas J. Kipps, MD, PhD, Jeffrey Alan Jones, MD, MPH, Susan Smith, Annette Jalayer, RN, Hagop M. Kantarjian, MD, Michael Keating, MD

Blood (2009) 114 (22): 3443.

https://doi.org/10.1182/blood.V114.22.3443.3443

Published: 2009

NARROW

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB In Chronic Lymphocytic Leukemia (CLL) Cells

The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies

The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway.

Plasma Circulating Ki-67 Index as a Biomarker and Prognostic Indicator in Patients with Chronic Lymphocytic Leukemia.

Symptom Profiles in Patients with Chronic Lymphocytic Leukemia: Validation and Application of the M. D. Anderson Symptom Inventory.

Clinical Relevance of Circulating Poly-Ubiquitin as a Prognostic Indicator in Chronic Lymphocytic Leukemia.

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Comparative Efficacy of First Line Therapies for Chronic Lymphocytic Leukemia: a Systematic Review and Meta-Analyses.

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only